Today: 21 May 2026
TBC Bank shares slide in London trade even as buyback ticks over
19 January 2026
1 min read

TBC Bank shares slide in London trade even as buyback ticks over

London, Jan 19, 2026, 14:15 GMT — Trading in regular session.

  • TBC Bank Group shares slipped roughly 1.1% in afternoon trading
  • Company announced a modest buyback, planning to cancel the repurchased shares
  • Broader UK equities dropped following new tariff threats that unsettled investors

Shares of TBC Bank Group Plc dipped on Monday, mirroring a broader sell-off among London-listed stocks, even though the lender revealed it continued repurchasing its own shares.

The FTSE 250 bank’s stock slipped 1.1% to 3,945 pence, after moving in a range from 3,870 to 4,005 pence during the session.

This move is significant since TBC, a lender centered on Georgia and expanding quickly in Uzbekistan’s digital sector, usually tracks changes in risk appetite. On Monday, sentiment shifted toward caution.

Capital returns are back in focus. Investors are closely watching if buybacks and dividends can anchor shares when macro headlines begin to dictate price moves.

London stocks dropped as U.S. President Donald Trump threatened tariffs on Britain and several European countries, hitting banks and other cyclical sectors, according to a Reuters report.

On Monday, TBC disclosed it bought 3,000 ordinary shares on January 16 at a volume-weighted average price of 3,872.98 pence via broker Peel Hunt. The shares are set for cancellation.

Buybacks reduce the number of shares available, potentially boosting earnings per share down the line. Still, Monday’s disclosed amounts were modest compared to daily trading volumes.

Peer Lion Finance Group, a London-listed lender tied to Georgia, slipped roughly 0.9% on the day, highlighting how stocks connected to the region were tracking with the broader market.

There’s a catch, though. Should tariff threats spiral into a full-blown trade war, the hit from global risk aversion could easily overwhelm company-specific boosts like buybacks. Plus, exposure to emerging markets would only magnify the volatility.

Investors are set to scrutinize any new updates from Washington and European capitals on tariffs before upcoming sessions. Attention will also turn to TBC’s 4Q and full-year 2025 results, due Feb. 20, followed by its Strategy Day on Feb. 24.

Stock Market Today

  • SpaceX Set to Go Public: Key Details and Market Impact
    May 20, 2026, 8:02 PM EDT. SpaceX, founded by Elon Musk, is poised to go public, joining hundreds of companies that raised $70 billion in U.S. equity markets last year. Going public means the company will offer shares for sale on stock exchanges, allowing investors to buy ownership stakes. This move could unlock significant capital for SpaceX's ambitious space ventures, while providing early investors a chance to realize gains. The offering is closely watched amid a strong appetite for tech and aerospace stocks, reflecting broader market interest in innovation-driven firms.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
QinetiQ share price rises on £205m Typhoon contract extension as BlackRock crosses 5%
Previous Story

QinetiQ share price rises on £205m Typhoon contract extension as BlackRock crosses 5%

Amazon stock on watch after AWS service issue — what to know before AMZN trades again
Next Story

Amazon stock on watch after AWS service issue — what to know before AMZN trades again

Go toTop